News

James Galvin, MD, MPH, director of the Comprehensive Center for Brain Health at the University of Miami Miller School of Medicine, provided insight on the unmet needs for dementia with Lewy bodies, and whether success in Alzheimer disease can help.

Using a cohort of more than 2500 patients with MS on disease-modifying therapies, treatment initiation within the first 2 years of disease onset was more beneficial on patient-reported outcomes than 2-4 years postonset.

The senior VP of clinical research at Eisai discussed findings from a phase 2 study assessing irsenontrine in patients with dementia with Lewy bodies and Parkinson disease dementia. [WATCH TIME: 4 minutes]

Here's some of what is coming soon to NeurologyLive® this week.

Chaired by Robert Bermel, MD, of Cleveland Clinic, the presentations also feature Jeffrey Cohen, MD; Amy Kunchock, MBBS, MMed; and Brandon Moss, MD. [WATCH TIME: 1 hour, 30 minutes]

The division director of pediatric neurology, and director of the pediatric sleep program at Cohen, Children's Medical Center, Northwell Health, spoke about sudden unexpected death in epilepsy and sleep at the 2022 AES Conference. [WATCH TIME: 3 minutes]

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is multiple sclerosis.

Short objective sleep duration was associated with weight regain and attenuated improvements in body composition one year after weight loss, independent of intervention allocation, age, and sex.

A recent review from the National MS Society revealed eight themes based on previous clinical trials focused on exercise and physical activity in MS.

Neurology News Network for the week ending December 17, 2022. [WATCH TIME: 4 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending December 16, 2022.

Almost 3 years since the beginning of the pandemic, continuous research efforts have begun to paint a better picture of the impact the virus has on the brain and the central nervous system.

The division director of pediatric neurology, and director of the pediatric sleep program at Cohen Children's Medical Center of Northwell Health, spoke about the association between sleep disorders and pediatric epilepsy at the 2022 AES annual meeting. [WATCH TIME: 3 minutes]

The director of the Headache Center at Allegheny Health Network provided perspective on whether focusing in on medications or lifestyle choices has better impacts on improving chronic migraine. [WATCH TIME: 4 minutes]

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Marwan Sabbagh, MD, FAAN. [LISTEN TIME: 21 minutes]

Findings from a recent randomized study demonstrated effective sleep maintenance of insomnia, as shown by increased sleep time and reduced awakenings, with low concentration of carbon dixoide.

In the largest collected of PML DNA samples, the study identified 4 immune-linked, high effect size, rare variants for use in an iatrogenic PML risk genetic test.

The clinical assistant professor in the division of Sleep Medicine, Department of Neurology, University of Michigan spoke about the associations of mental health with insomnia in transgender youth. [WATCH TIME: 5 minutes]

AOC 1001, an agent consisting of a proprietary monoclonal antibody that binds to the transferrin receptor 1, was safe, tolerable, and showed significant reductions in DMPK, a disease-related mRNA.

The clinical assistant professor in the division of Sleep Medicine, Department of Neurology, University of Michigan, spoke about sleep disorders associated with transgender youths. [WATCH TIME: 4 minutes]

Although the effects of the educational intervention weren’t seen at 3 months, investigators noticed significant differences relative to standard of care at 12 months.

A recent review suggests that children might be affected by specific types of insomnia and that their treatment should be more suitable to their classified insomnia phenotype.

The chief medical officer of Alzheon detailed the efficacy, safety, and potential of ALZ-801, an investigational anti-amyloid therapy being assessed in high-risk individuals with early Alzheimer disease.

In a phase 3 trial, NurOwn failed to meet its primary end point of change on ALSFRS-R; however, the therapy showed significant benefits in those with less severe forms of ALS.

Episode 28 of the AUPN Leadership Minute features Donald S. Higgins, MD, of the VHA; and Gabriele C. De Luca, MD, DPhil, FRCPath, FAAN, of University of Oxford. [WATCH TIME: 5 minutes]

A recent phase 2 study showed a significant decline in wakefulness after sleep onset across both doses of sunobinop for individuals with insomnia recovery from alcohol use disorder.

The professor of medicine at the University of Manitoba discussed the need to change how multiple sclerosis is characterized, and how aging contributes to increased disease progression. [WATCH TIME: 4 minutes]

Bjoern Schelter, MD, Data Analytics and Biostatistics lead at TauRx, provided background on the efficacy, safety, and role of HMTM as a treatment for cognition in pre-Alzheimer disease stages like mild cognitive impairment.

Catch up on any of the neurology news headlines you may have missed over the course of the last month, compiled all into one place by the NeurologyLive® team.

The pediatric epilepsy specialist at Weill Cornell Medicine in New York City spoke on how meetings such as the 2022 AES Conference bring clinicians together as well as how parents motivate them to advance pediatric epilepsy research. [WATCH TIME: 6 minutes]